Arcturus Therapeutics Ltd (ARCT) Given Average Recommendation of “Hold” by Analysts
Arcturus Therapeutics Ltd (NASDAQ:ARCT) has been given a consensus rating of “Hold” by the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $3.45.
ARCT has been the topic of several recent analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Arcturus Therapeutics in a research report on Wednesday, November 29th. They set a “buy” rating on the stock. Chardan Capital initiated coverage on shares of Arcturus Therapeutics in a research report on Monday, January 22nd. They set a “buy” rating and a $12.00 price objective on the stock.
Arcturus Therapeutics (NASDAQ:ARCT) opened at $5.93 on Friday. Arcturus Therapeutics has a 1-year low of $5.78 and a 1-year high of $15.19. The firm has a market cap of $73.45, a P/E ratio of -1.48 and a beta of 1.44.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.